Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
Mantripragada KC, Olszewski AJ, Schumacher A, Perez K, Birnbaum A, Reagan JL, Mega A, Khurshid H, Bartley C, Lombardo A, Rossiter R, Papa A, Bakalarski P, Safran H. Mantripragada KC, et al. Among authors: olszewski aj. J Oncol Pract. 2016 Apr;12(4):e396-404. doi: 10.1200/JOP.2015.008433. Epub 2016 Feb 23. J Oncol Pract. 2016. PMID: 26907448
Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
Ollila TA, Olszewski AJ, Butera JN, Quesenberry MI, Quesenberry PJ, Reagan JL. Ollila TA, et al. Among authors: olszewski aj. Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):204-209. doi: 10.1016/j.clml.2018.01.007. Epub 2018 Jan 31. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29433979
Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
Chorzalska A, Ahsan N, Rao RSP, Roder K, Yu X, Morgan J, Tepper A, Hines S, Zhang P, Treaba DO, Zhao TC, Olszewski AJ, Reagan JL, Liang O, Gruppuso PA, Dubielecka PM. Chorzalska A, et al. Among authors: olszewski aj. Mol Oncol. 2018 May;12(5):630-647. doi: 10.1002/1878-0261.12186. Epub 2018 Apr 6. Mol Oncol. 2018. PMID: 29485707 Free PMC article.
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. Castillo JJ, et al. Among authors: olszewski aj. Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12. Br J Haematol. 2019. PMID: 29527667 Free article. Clinical Trial. No abstract available.
170 results